Selective inhibition of neuronal nitric oxide synthase (nNOS) has been shown to prevent brain injury and is important for the treatment of various neurodegenerative disorders. This study shows that not only greater inhibitory potency and isozyme selectivity but more druglike properties can be achieved by fragment hopping. On the basis of the structure of lead molecule 6, fragment hopping effectively extracted the minimal pharmacophoric elements in the active site of nNOS for ligand hydrophobic and steric interactions and generated appropriate lipophilic fragments for lead optimization. More potent and selective inhibitors with better druglike properties were obtained within the design of 20 derivatives (compounds 7-26). Our structure-based inhibitor design for nNOS and SAR analysis reveal the robustness and efficiency of fragment hopping in lead discovery and structural optimization, which implicates a broad application of this approach to many other therapeutic targets for which known druglike small-molecule modulators are still limited.
Selective inhibition of neuronal nitric oxide synthase (n class="Gene">nNOS) has been shown to prevent brain injury and is important for the treatment of various neurodegenerative disorders. This study shows that not only greater inhibitory potency and isozyme selectivity but more druglike properties can be achieved by fragment hopping. On the basis of the structure of lead molecule 6, fragment hopping effectively extracted the minimal pharmacophoric elements in the active site of nNOS for ligand hydrophobic and steric interactions and generated appropriate lipophilic fragments for lead optimization. More potent and selective inhibitors with better druglike properties were obtained within the design of 20 derivatives (compounds 7-26). Our structure-based inhibitor design for nNOS and SAR analysis reveal the robustness and efficiency of fragment hopping in lead discovery and structural optimization, which implicates a broad application of this approach to many other therapeutic targets for which known druglike small-molecule modulators are still limited.
Authors: P Martasek; Q Liu; J Liu; L J Roman; S S Gross; W C Sessa; B S Masters Journal: Biochem Biophys Res Commun Date: 1996-02-15 Impact factor: 3.575
Authors: Anthony V Pensa; Maris A Cinelli; Huiying Li; Georges Chreifi; Paramita Mukherjee; Linda J Roman; Pavel Martásek; Thomas L Poulos; Richard B Silverman Journal: J Med Chem Date: 2017-08-04 Impact factor: 7.446
Authors: Kristin Jansen Labby; Fengtian Xue; James M Kraus; Haitao Ji; Jan Mataka; Huiying Li; Pavel Martásek; Linda J Roman; Thomas L Poulos; Richard B Silverman Journal: Bioorg Med Chem Date: 2012-02-07 Impact factor: 3.641
Authors: Qing Jing; Huiying Li; Georges Chreifi; Linda J Roman; Pavel Martásek; Thomas L Poulos; Richard B Silverman Journal: Bioorg Med Chem Lett Date: 2013-08-14 Impact factor: 2.823
Authors: Silvia L Delker; Haitao Ji; Huiying Li; Joumana Jamal; Jianguo Fang; Fengtian Xue; Richard B Silverman; Thomas L Poulos Journal: J Am Chem Soc Date: 2010-04-21 Impact factor: 15.419
Authors: Suma Rao; Zhenlang Lin; Alexander Drobyshevsky; Lina Chen; Xinhai Ji; Haitao Ji; Yirong Yang; Lei Yu; Matthew Derrick; Richard B Silverman; Sidhartha Tan Journal: Dev Neurosci Date: 2011-07-08 Impact factor: 2.984
Authors: Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman Journal: J Med Chem Date: 2013-03-27 Impact factor: 7.446
Authors: Fengtian Xue; Jianguo Fang; William W Lewis; Pavel Martásek; Linda J Roman; Richard B Silverman Journal: Bioorg Med Chem Lett Date: 2009-11-22 Impact factor: 2.823